We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
![Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies](https://www.ohe.org/wp-content/uploads/2023/01/Cancer_WellcomeCollection_landscape.jpg)
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
![Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations](https://www.ohe.org/wp-content/uploads/2023/01/Healthcare-systems_AdobeStock_Rawpixel.com_landscape.jpg)
Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making
![FINAL_OHE HVMF White Paper 2021_for posting 2-01](https://www.ohe.org/wp-content/uploads/2021/11/FINAL_OHE-HVMF-White-Paper-2021_for-posting-2-01.png)
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
![Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies](https://www.ohe.org/wp-content/uploads/2020/08/Bridge-150x150.png)
- 01
- 02